Phase II Clinical Trial Shows Promising Results for New Cancer Treatment

Author(s): Greenery Ancola

A recent phase II clinical trial has shown promising results for a new cancer treatment. The trial, which involved a group of patients with advanced stage cancer, showed a significant increase in survival rates and a reduction in tumor size. The new treatment, called PD-L1 inhibitors, works by targeting a specific protein that is found in many cancer cells. The drug works by blocking this protein, which allows the body’s immune system to attack and kill the cancer cells. The trial was conducted over a period of two years and involved over 100 patients. The patients received the PD-L1 inhibitor drug in combination with chemotherapy.